Repirinast

Drug Profile

Repirinast

Alternative Names: BAY U 2372; BAY W 8199; MY 5116; Romet

Latest Information Update: 15 Feb 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Mitsubishi Chemical
  • Developer Bayer; Mitsubishi Chemical; Mitsubishi Tanabe Pharma Corporation
  • Class Antiallergics; Antiasthmatics; Quinolones
  • Mechanism of Action Histamine release inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Marketed Asthma

Most Recent Events

  • 01 Oct 2007 Mitsubishi Pharma Corporation has merged with Tanabe Seiyaku to form Mitsubishi Tanabe Pharma Corporation
  • 24 Apr 2001 Mitsubishi-Tokyo Pharmaceuticals has reacquired exclusive Japanese marketing rights to repirinast from Nikken Chemical
  • 16 Nov 1999 Tokyo Tanabe has been acquired by Mitsubishi Chemical
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top